Skip to main content
. 2022 Sep 5;25(10):105067. doi: 10.1016/j.isci.2022.105067

Figure 3.

Figure 3

Anti-drug antibody responses against VRC01v23 infusions and effect on pharmacokinetics

(A) Plasma anti-drug antibody ELISA endpoint titers against the bNAb VRC01v23 (ADA, dashed lines) and bNAb pharmacokinetics (PK, solid lines) after one 10 mg/kg IV infusion (blue arrow) in naive animals which did not receive anti-CD20 (control).

(B) ADA endpoint titers (dashed lines, LOD = 50) and VRC01v23 PK (solid lines) after three 10 mg/kg IV infusions (blue arrows) in SHIV-infected animals which received anti-CD20 (treatment). Each point in the PK curves represent the mean of at least two replicates and the error bar represents the standard error. See also Figure S4.